A global virtual event dedicated to the latest cardio-renal-metabolic disease treatment strategies to support better patient outcomes

 

Overview

KDIGO and Translational Medicine Academy (TMA), in partnership with Radcliffe Cardiology, are excited to announce e-SPACE Cardio-Renal-Metabolic (CRM), taking place 10–11 April 2026.

Cardio-kidney-metabolic (CKM) health reflects the complex interactions between metabolic risk factors, diabetes, chronic kidney disease and the cardiovascular system – major drivers of global morbidity and mortality. To address these challenges, TMA and KDIGO’s e-SPACE CRM programme empowers clinicians worldwide to improve patient outcomes.

The 2026 conference offers free, cutting-edge virtual education, uniting leaders in cardiology, nephrology and diabetology. Participants can engage through concise expert talks, live panels and interactive “meet the expert” sessions, blending global and regional insights.

Following the success of e-SPACE CRM 2025, which brought together 60 experts and almost 3,000 healthcare professionals, the 2026 event will advance professional development and support KDIGO’s mission to improve kidney care globally.

Guided by an esteemed international faculty and TMA’s educational expertise, e-SPACE CRM 2026 is set to be a leading online conference for the cardio-renal-metabolic community.

Watch e-SPACE CRM 2025 on-demand here.

Event starts in:

Share this event:

Programme

(Please note this programme is subject to change)

Day 1

8:10 AM - 8:50 AM (BST)
Keynote Session
Keynote Lecture

9:10 AM - 9:50 AM (BST)
Meet the Experts
Meet the Experts

10:00 AM - 11:00 AM (BST)
Plenary Session
Session 1 – Optimising Outcomes for Patients With Cardio-Renal-Metabolic (CRM) Disease

Chairs – Andrew Coats and Manisha Sahay

  • The Urgency and Rationale of Addressing CRM in Our Patients – Brendon Neuen

  • The Role of Primary Care – Ana Cebrián Cuenca

  • Staging CKM Disease – Merlin Thomas

  • The Role of Imaging – Victoria Delgado

  • Panel Discussion



11:10 AM - 11:50 AM (BST)
Meet the Experts
Meet the Experts

12:00 PM - 1:00 PM (BST)
Plenary Session
Session 2 – Evolving Guidelines in CKM

Chair Christoph Wanner

  • Integrated Care: The Rationale for Simpler, Unified Guidelines – Joao Ferreira

  • Standards of Care in Diabetes 2026: Chronic Kidney Disease and Risk Management – Sylvia Rosas

  • KDIGO Update: New Perspectives in Kidney Health

  • iCardio Guidelines: Global Cascade Guidelines on Obesity and HF – Vijay Chopra

  • Assessing Metabolic Disorders: The EAS Perspective – Stefano Romeo

  • Panel Discussion



1:10 PM - 1:50 PM (BST)
Keynote Session
Keynote Lecture

2:10 PM - 2:50 PM (BST)
Meet the Experts
Meet the Experts

3:00 PM - 4:00 PM (BST)
Plenary Session
Session 3 – Foundational (and Almost Foundational) Therapies in CRM

ChairsAntonio Ceriello and Nisha Bansal

  • SGLT2 Inhibitors – Nisha Bansal

  • MRAs?! – Maja Cikes

  • GLP1 RA?! – Naveed Sattar

  • ASI – Shahzeb Khan

  • Panel Discussion



4:10 PM - 4:50 PM (BST)
Meet the Experts
Meet the Experts

5:00 PM - 6:00 PM (BST)
Plenary Session
Session 4 – Anti-Obesity Medication (AOMs) Clinical Experience

ChairsMarc-André Cornier and James Burton

  • The Nephrologist View

  • The Diabetologist View – Jennifer Green

  • The Cardiologist View – Javed Butler

  • Muscle-Wasting Associated With AOMs – Stefan Anker

  • Panel Discussion



7:10 PM - 7:50 PM (BST)
Meet the Experts
Meet the Experts

8:00 PM - 9:00 PM (BST)
Plenary Session
Session 5 – Non-Steroidal MRAs

ChairNisha Bansal

  • Non-Steroidal vs. Steroidal MRAs – What Clinicians Need to Know

  • Finerenone in CKD: Managing Patients at High Risk of Heart Failure

  • Expanding the Spectrum: Finerenone in Heart Failure Across CKM Risk Profiles – Justin Ezekowitz

  • Expanding the Spectrum: Finerenone in T1D – Hiddo Heerspink

  • Panel Discussion



9:10 PM - 9:50 PM (BST)
Meet the Experts
Meet the Experts

10:00 PM - 11:00 PM (BST)
Plenary Session
Session 6 – Improving Outcomes in HFpEF: New Frontiers

ChairsBarry Borlaug

  • What is HFpEF? – John McMurray

  • Obesity is HFpEF & HFpEF is Obesity?! – Milton Packer

  • Diagnostic Challenges: Identifying HFpEF in Clinical Practice – Cristina Gavina

  • Management Strategies: Current and Emerging Therapies

  • Panel Discussion




Day 2

9:10 AM - 9:50 AM (BST)
Meet the Experts
Meet the Experts

10:00 AM - 11:00 AM (BST)
Plenary Session
Session 7 – Obesity as a Central Player in CRM

ChairsCarel Le Roux and Carol Pollock

  • Clinical Frameworks: Recent Definitions and Evolving Classifications of Obesity

  • The Kidney and Obesity: Mechanisms of Renal Injury

  • Type 2 Diabetes and Obesity

  • Sarcopenic Obesity – Stephan von Haehling

  • Panel Discussion



11:10 AM - 11:50 AM (BST)
Meet the Experts
Meet the Experts

12:00 PM - 1:00 PM (BST)
Plenary Session
Session 8 – Managing Key Parameters in CRM

ChairShazeb Khan

  • Potassium Levels – Patrick Rossignol

  • Albuminaria – David Wheeler

  • NT ProBNPs – Evangelos Giannitsis

  • Low eGFR – James Burton

  • Low Sodium – Julio Núñez

  • Lipids – Pierre François Sabouret

  • Panel Discussion



2:10 PM - 2:50 PM (BST)
Meet the Experts
Meet the Experts

3:00 PM - 4:00 PM (BST)
Plenary Session
Session 9 – Combination Therapies for CKM

Chair Giuseppe Rosano

  • Synergistic Effects: Combination Therapy With Finerenone and Empagliflozin – Jennifer Green

  • The EASi-KIDNEY Trial: New Evidence in Renal Protection

  • The Polypill: Can Simplification Change the Treatment Landscape? – Piotr Ponikowski

  • Combining Incretins With Muscle Anabolics – Stefan Anker

  • Panel Discussion



4:10 PM - 4:50 PM (BST)
Meet the Experts
Meet the Experts

5:00 PM - 6:00 PM (BST)
Plenary Session
Session 10 – From Prevention to Shared Decision-Making

ChairFausto Pinto

  • Cardiometabolic Health in the Course of Women’s Life – Glaucia Moraes de Oliveira

  • Implementation Science in the Path Toward Pharmacoequity – Dinushika Mohottige

  • The LATTICE Initiative – Ankeet Bhatt

  • Panel Discussion




Course Leadership

Joao Ferreira

Joao Ferreira
Course Director
University of Porto, Porto, PT

Shahzeb Khan

Shahzeb Khan
Course Director
Baylor Scott & White Health, Dallas, US

Shelley Zieroth

Shelley Zieroth
Course Director
University of Manitoba, Winnipeg, CA

Faculty

Stefan Anker
Stefan Anker

Charité Campus Virchow-Klinikum, Berlin, DE

Nisha Bansal
Nisha Bansal

University of Washington, Seattle, US

Ankeet Bhatt
Ankeet Bhatt

Kaiser Permanente San Francisco Medical Center, San Francisco, US

Barry Borlaug
Barry Borlaug

Mayo Clinic and Foundation, Rochester, US

James Burton
James Burton

University of Leicester, Leicester, UK

Javed Butler
Javed Butler

University of Mississippi Medical Center, Jackson, US

Ana Maria Cebrián Cuenca
Ana Maria Cebrián Cuenca

Centro de Salud San Antón, Murcia, ES

Antonio Ceriello
Antonio Ceriello

IRCCS MultiMedica, Milan, IT

Andrew Coats
Andrew Coats

Monash University, Melbourne, AU

Marc-Andre Cornier
Marc-Andre Cornier

Medical University of South Carolina, Charleston, US

Justin Ezekowitz
Justin Ezekowitz

University of Alberta, Edmonton, CA

Cristina Gavina
Cristina Gavina

University of Porto, Porto, PT

Jennifer Green
Jennifer Green

Duke Clinical Research Institute, Durham, US

Hiddo Heerspink
Hiddo Heerspink

University Medical Center Groningen, Groningen, NL

Carel Le Roux
Carel Le Roux

University College Dublin, Dublin, IE

John McMurray
John McMurray

University of Glasgow, Glasgow, UK

Milton Packer
Milton Packer

Baylor University Medical Center, Texas, US

Fausto Pinto
Fausto Pinto

Santa Maria Hospital - CHULN, Lisbon, PT

Carol Pollock
Carol Pollock

The University of Sydney, Camperdown, AU

Stefano Romeo
Stefano Romeo

University of Gothenburg, Gothenburg, SE

Patrick Rossignol
Patrick Rossignol

CHRU de Nancy, Nancy, FR

Manisha Sahay
Manisha Sahay

Osmania General Hospital, Hyderabad, IN

Merlin Thomas
Merlin Thomas

Monash University, Melbourne, AU

Learning Objectives

  • Review the burden of diabetes, kidney disease and heart failure including morbidity, excess mortality and reduced quality of life affecting individuals around the world

  • Describe the complexity and interlink between the three conditions

  • Discuss existing guidelines and best approaches for screening patients

  • Review evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease and obesity including SLGT2i, GLP-1RA, new non-steroidal mineralocorticoid receptor antagonists and other emerging therapies

  • Foster cross-collaboration between other cardiorenal / metabolic specialists and primary care physicians and allied health care professionals in order to improve patients outcomes

Target Audience

  • Cardiologists

  • Nephrologists

  • Diabetologists

  • General Practitioners (GPs)

  • HF Specialists

  • Nurses, Pharmacists and other Allied Healthcare Professionals

If you’re interested in becoming an educational partner or sponsor at this event, please contact [email protected]

About KDIGO

KDIGO is a global organisation developing and implementing evidence-based clinical practice guidelines in kidney disease. It is an independent, volunteer-led, self-managed foundation incorporated in Belgium and accountable to the public and the patients it serves.

KDIGO’s mission is to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines.

For more information on KDIGO, please visit https://kdigo.org.

About Translational Medicine Academy

Our ambition at the Translational Medicine Academy® (TMA) is to bring medical findings from bench to bedside and into the working lives of physicians and the care of patients. In seeking to improve therapeutic approaches, TMA works with its International Scientific Advisory Board on Critical Mission Areas® of public health importance in domains where there are educational shortcomings among physicians and unmet healthcare needs among patients.

Gathered around a Scientific Advisory Board of experts, the Translational Medicine Academy is an international non-profit Foundation with headquarter in Basel, and offices in Paris, and the US. TMA’s funding includes private donations from individuals and educational grants from governments, non-governmental organizations and corporations.

For more information on TMA, please visit www.tmacademy.org.

About Radcliffe Cardiology

We are Radcliffe, a knowledge network for the cardiovascular community

We’re here to bring cardiovascular knowledge, insight and innovation to life for clinicians around the world, using our communications and creative expertise, our platforms and connections across the community to help transform theory into practice faster and more effectively.

We bring medical knowledge to life

From great science writing and smart journal editing, the curation of evidence based and peer-reviewed content, to engaging new formats that cut through the noise, we believe that communication is at the heart of great healthcare.

Our work is underpinned by 3 core principles:

  • We build on the best science

  • We work hands-on with our community

  • We bring fresh thinking


Our promise is that we’ll equip you with the latest knowledge and skills you need, to do the best for your patients.

For more information on Radcliffe Cardiology, please visit www.radcliffecardiology.com.

Please contact [email protected] should you have any queries.